On February 4, 2022 Scandion Oncology A/S, the Cancer Drug Resistance Company, reported that a member of management discharging managerial responsibilities has purchased shares in the company (Press release, Scandion Oncology, FEB 4, 2022, View Source,c3497586 [SID1234607750]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s Chief Operating Officer, Maj Hedtjärn has reported that she has bought 8,000 shares in December 2021. This brings her total shareholding up to 24,000 shares.

Persons under an obligation to report are persons discharging managerial responsibilities, as well as persons closely associated with them.